In 2024, the AI biotech firm Insilico Medicine faced a pivotal decision about its new drug, Rentosertib. Discovered and designed using artificial intelligence to treat a lung disease, Rentosertib had successfully advanced to Phase II trials - a first in global pharmaceutical history. Insilico could license the drug, consistent with its low-risk, revenue-generating model, or continue internal development to validate its full-stack AI capabilities. The decision would shape not only the future of Rentosertib, but also how Insilico balanced risk and ambition in deploying its AI tools-defining its identity as either a bold full-stack clinical innovator or a disciplined pioneer in early-stage discovery.